Introduction
As the sensitivity of cytogenetic and PCR-based methods for the monitoring of chronic myeloid leukaemia (CML) has improved over time, it has become evident that the achievement of clinical, morphological and cytogenetic remission does not indicate eradication of the disease. For months or years after achieving a complete cytogenetic response (absence of Philadelphia (Ph)-positive cells in at least 20 bone marrow metaphase cells) the majority of CML patients have measurable disease by real-time reverse transcriptase quantitative PCR (RQ-PCR), and would relapse if imatinib treatment were withdrawn. 1, 2 However, in the majority of patients who respond to imatinib there is a progressive decline in BCR-ABL mRNA over time, so that after several years of treatment an increasing number of chronic-phase CML patients will achieve a complete molecular response (CMR), with no BCR-ABL mRNA detectable by RQ-PCR. Whether the CML clone has been eradicated in any of these patients is a question of increasing clinical and scientific importance. The complete elimination of CML would require CMR, but CMR is not a guarantee of eradication of the leukaemia, because the significance of CMR is determined by the detection limit of the assay that is used.
Leukaemic cells can be identified by the presence of the Ph chromosome on cytogenetic analysis and/or the BCR-ABL fusion gene as detected by PCR. This enables a quantitative assessment of the burden of leukaemia and its response to treatment. The primary method of quantification of minimal residual disease (MRD) is RQ-PCR. Results are expressed as a ratio of BCR-ABL to a control gene. The RQ-PCR method and the choice of control gene differ between laboratories, so that the median baseline BCR-ABL:control gene ratio is not the same in all laboratories, making it difficult to compare results between centres. In order to overcome this difficulty, an international collaborative effort has led to the development of an international scale for the reporting of BCR-ABL mRNA levels, in which each result is normalized using a laboratory-specific conversion factor. [3] [4] [5] For instance, on the international scale, a 2-log reduction from the median pre-treatment BCR-ABL level (determined in a pool of patients) is 1%. On the assumption that almost 100% of the cells are leukaemic at diagnosis, a BCR-ABL level of 1% may be viewed as indicating that the proportion of residual leukaemic cells is approximately 1% of that present at diagnosis.
Both on imatinib and on interferon-a (IFN) treatment, the achievement of a deeper cytogenetic response is associated with improved progression-free survival. 6, 7 Within 18 months a complete cytogenetic response is observed in around 80% of the patients treated up-front with imatinib, and yet, even in this low-risk group, it has been demonstrated that a further reduction of the level of residual disease to p0.1% BCR-ABL, termed a major molecular response (MMR), is associated with an improvement in progression-free survival. 8 A proposed definition of CMR requires undetectable BCR-ABL transcripts in an RQ-PCR assay with a calculated sensitivity of at least 1.5 log below the level of MMR, and confirmed on subsequent testing. 9 In a subset of patients in the International Randomised Study of Interferon versus STI571 (IRIS) study, 6 loss of MMR was observed in 0/18 patients in CMR versus 6/22 (27%) of those in MMR who still had detectable BCR-ABL, 9 suggesting that CMR confers a more stable response. However, as the progression-free survival of patients in MMR is close to 100%, 8 it may be impossible to demonstrate that patients in CMR have a survival advantage over patients in MMR with detectable BCR-ABL, even if CMR does confer a better prognosis. Most of the available evidence suggests that prognosis improves as the level of MRD falls. It has not been proven that CMR confers a better prognosis than MMR, but this makes sense from first principles.
Measuring the level of MRD
In RQ-PCR, the target gene, BCR-ABL, is reverse transcribed in parallel with a control gene, such as BCR. The number of copies of the control gene that can be detected in an individual sample will vary according to the amount of sample, the sample quality, and the efficiency of the reverse transcription reaction and the real-time PCR. The estimated limit of detection of RQ-PCR varies between laboratories, but is generally in the range of 10 À4 -10 À5 . Some laboratories perform nested PCR if BCR-ABL is not detectable in RQ-PCR, and have found that negative nested PCR represents a more stringent definition of CMR. 10 Yet, other laboratories (including our own 11 ) have found no improvement in the limit of detection of RQ-PCR using the conventional nested PCR for amplification of BCR-ABL complementary DNA.
12 Such methodological differences highlight the need for a standardized definition of CMR for use in clinical trials.
Regardless of the PCR methodology in use, a major determinant of the sensitivity of the assay is the amount of patient material that is sampled. 13, 14 This can be illustrated by considering the level of residual disease in complete cytogenetic response. If the Ph chromosome is not detected in 20 metaphase cells, one might assume that the level of MRD is o5%. Allowing for sampling error, which can be modelled using Poisson statistics, there is a 95% probability that the true level of MRD is o14%. The lower limit of detection can be improved simply by increasing the number of cells examined.
Virtually all patients with chronic-phase CML express one or both of the common e13a2 and e14a2 BCR-ABL mRNA transcripts. In any type of reverse transcriptase PCR this results in a risk of cross-contamination between patient samples when batches of samples containing variable levels of BCR-ABL are processed together. If stringent controls are in place to exclude mRNA cross-contamination, it is possible for a highly sensitive nested PCR method to achieve a sensitivity well below that of conventional RQ-PCR, 15 but such methods are not practical for routine clinical use. Furthermore, the finding of occasional BCR-ABL mRNA transcripts in the blood of normal individuals 15, 16 poses a limit to the specificity of highly sensitive PCR methods for the monitoring of MRD based on mRNA. This has led us and others to investigate the use of patient-specific BCR-ABL genomic DNA breakpoints as an investigational test to improve the lower limit of detection of MRD. [17] [18] [19] [20] In order to perform patient-specific DNA PCR in CML, it is necessary to identify the BCR-ABL fusion region and to design primers for each patient to ensure specificity for the unique fusion sequence (Figure 1) . The use of a patient-specific DNA sequence as the marker of the leukaemic clone is well established in acute lymphoblastic leukaemia, in which the target sequence is either the immunoglobulin gene or the T cell receptor gene rearrangement. 21 Sensitive PCR methods, including optimized RQ-PCR, are capable of detecting a single copy of BCR-ABL, if there is a copy present in the sample. 22 However, regardless of the method used to quantify the level of MRD, it is impossible formally to demonstrate complete eradication of the CML clone, because it is not possible to test every single haematopoietic cell in the body. Serial MRD measurements during imatinib treatment may be used to extrapolate an approximate level of MRD after BCR-ABL is no longer detectable, but the accuracy of kinetic Figure 1 Patient-specific DNA PCR for genomic BCR-ABL. A method for the detection of the BCR-ABL fusion sequence is shown. In most cases the BCR and ABL1 breakpoints are intronic and the region containing the fusion sequence is spliced out of the mRNA. Quantification of the patient-specific BCR-ABL DNA sequence is based on real-time PCR using a nested primer and probe set.
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The last CML cell? DM Ross et al modelling is dependent on assumptions made about the rate of depletion of leukaemic cells over time. Ultimately, if the level of BCR-ABL is below the limit of detection, the only way to determine whether there is persistent residual disease is to withdraw therapy and monitor closely for evidence of molecular relapse. If molecular relapse occurs after the withdrawal of therapy, it can be concluded that MRD was present. On the other hand, if CMR is maintained in the long term, both leukaemia eradication and continuing suppression of residual leukaemia are plausible explanations.
Kinetics of response to imatinib treatment
A plot of BCR-ABL RQ-PCR data from imatinib-treated chronicphase CML patients reveals a biphasic response. 23 The first phase of the imatinib response has a steep downward gradient, reflecting rapid clearance of mature CML progeny, and is associated with the achievement of haematological and cytogenetic response. The second phase has a shallow gradient and is thought to reflect gradual depletion of the CML granulocyte-macrophage precursor (GMP) pool. 24 The latter phenomenon may be prognostically important, because it is in the GMP fraction of CML cells that transformation to myeloid blast crisis is thought to occur. 25 The response to imatinib varies considerably between chronic-phase CML patients, despite the apparent homogeneity of the disease. Patients with a low-risk Sokal score at diagnosis, for instance, are more likely to achieve an MMR. 8, 26, 27 Around 40% of the patients achieve an MMR within the first year 8 and only 5% of patients achieve a CMR within the first 2 years, 9 even though the rate of CMR reaches 40-50% after 5 years of imatinib treatment. CML progenitors are relatively resistant to imatinib, 28, 29 and their slow depletion during imatinib treatment may reflect the induction of apoptosis in a manner that is dependent on the cell cycle. Beyond the second year of treatment the reduction in BCR-ABL mRNA is o0.5 log per annum in the majority of patients. 9, 24 On the assumption that patients enter CMR with an MRD burden of the order of 10 6 cells, one could extrapolate that few patients would achieve eradication of the leukaemic clone, until after at least 10 years in CMR on continuing imatinib treatment.
Eradication of CML stem cells
Extensive studies on CML stem cells in vitro have shown multiple pathways of resistance to tyrosine kinase inhibitors. 28 These include decreased intracellular uptake and retention of cytotoxic drugs and tyrosine kinase inhibitors, 28 and resistance to apoptosis. 30, 31 Decreased expression of human leukocyte antigen co-stimulatory molecules and targets of adaptive immunity (such as myeloid granule proteins) might also protect stem cells from immune surveillance. 32, 33 Many characteristics are shared by leukaemic and normal stem cells, making it difficult to develop a stem cell targeted therapy that is effective against CML and relatively non-toxic. Treatment with imatinib and other ABL kinase inhibitors in vitro results in an increase in quiescent CML stem cells that retain proliferative capacity when treatment is withdrawn. 34, 35 Various factors that may contribute to the persistence of leukaemia after imatinib treatment are summarized in Figure 2 . These data would lead SPOTLIGHT Figure 2 Some factors that might contribute to the persistence of MRD in CML. A wide range of factors intrinsic to the leukaemic clone or intrinsic to the patient (constitutional factors) may influence the response to therapy and the ultimate persistence or eradication of the leukaemic clone. These factors are summarized in this schematic diagram. Pharmacokinetics: increased bioavailability of imatinib or decreased clearance may enhance systemic drug exposure and kinase inhibition. Imatinib absorption in the gut is influenced by ATP-binding cassette sub-family B member 1 (ABCB1) and ATP-binding cassette sub-family G member 2 (ABCB2) and hepatic clearance is mediated by cytochrome P450 enzymes. 80, 81 Cellular influx/efflux: the intracellular concentration of imatinib is dependent on the balance between the influx and efflux of the drug. Imatinib influx is organic cation transporter-1 dependent and organic cation transporter-1 activity varies between patients. 82 Imatinib may be a substrate of the efflux proteins, ABCB1 and ABCB2. 83, 84 Immunity: CML cells may evade immune recognition by downregulation of HLA molecules or leukaemia-associated antigens, or by downregulation of T cell co-stimulatory signals. CTLs and NK cells may be cytotoxic against CML cells.
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Autocrine/paracrine growth factors: CML cells produce cytokines that have anti-apoptotic effects. 30, 31 Stromal homing: CML cells have abnormal interactions with tissue stroma, and stromal interactions may protect leukaemic cells from apoptosis. 86, 87 BCR-ABL expression: high expression of BCR-ABL may be observed in advanced-phase CML 88 and in CML stem cells, 28 and may be associated with resistance to imatinib treatment.
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In contrast, two studies of kinetic modelling found that CML might be eradicated by prolonged imatinib treatment. In one model, stem cells were depleted on the basis that susceptibility to apoptosis in response to imatinib is restored as quiescent stem cells enter the cell cycle. 24 Long-term stem cells enter the cell cycle infrequently, and were therefore depleted very gradually in the model. A second study reached the same conclusion, but for a different reason. 36 The authors incorporated in their model the stochastic process of stem cell exhaustion. Put simply, each time a precursor cell divides it gives rise to two daughter cells and each of these daughter cells will be committed either to differentiation or to self-renewal. The probability of each of these 'choices' is dependent upon the position of the cell in the haematopoietic hierarchy; more mature precursor cells are more likely to commit to differentiation. Although, on average, a sufficient number of stem cells will commit to self-renewal, in the case of a single leukaemic stem cell it is possible that both progeny should commit to differentiation and the leukaemic stem cell would then be extinct. Based on assumptions about stem cell biology the authors constructed a mathematical model of CML that incorporated a stochastic process of stem cell renewal versus differentiation. In most iterations of the model the CML stem cell pool was already exhausted before the 'patient' commenced treatment and the proportion of 'patients' in whom the CML stem cell pool became extinct rose progressively during imatinib treatment. As with any disease model, the validity of these predictions is dependent upon the accuracy of the assumptions from known disease biology. Considering this caveat, we have at least two potential explanations for why a treatment that is apparently cytostatic to stem cells could still have curative potential in CML.
Transplantation
Allogeneic stem cell transplantation remains the only therapy for CML that has been shown to achieve a durable CMR, with longterm follow-up in excess of a decade, described by Goldman as an 'operational cure'. 37 Myeloablative conditioning for transplantation may result in a profound reduction in leukaemic burden, but it appears that this alone is not sufficient to achieve long-term control of the leukaemia. A graft-versus-leukaemia immunological effect contributes to the long-term success of the treatment, as evidenced by the higher relapse risk in syngeneic transplants than in allografts, and by the efficacy of response to donor lymphocyte infusion.
Even in allograft recipients it is uncertain whether MRD has been eradicated. Very late relapses may occur even after decades 38 and low levels of BCR-ABL mRNA may be detected intermittently without overt relapse. 39, 40 In order to determine whether rare BCR-ABL transcripts truly reflect persistence of the original CML clone, we performed patient-specific BCR-ABL DNA PCR in patients in long-term remission post-allograft. These results showed that in most cases occasional detectable BCR-ABL transcripts were not associated with detectable BCR-ABL DNA, indicating that these low-level positive RQ-PCR results are not reliable indicators of residual disease. Although the majority of allograft patients in long-term remission had no detectable BCR-ABL DNA, it remains possible that MRD persists below the limit of detection.
Interferon treatment
The mechanism of action of IFN in CML is unclear, but may involve antiproliferative effects, 41 altered stem cell self-renewal, 42 pro-apoptotic effects 43 and augmentation of naturally occurring immunological responses against leukaemia-associated antigens. [44] [45] [46] Complete cytogenetic responses occur in up to 20-30% of chronic-phase patients treated with IFN (±cytarabine) and such patients have a significant improvement in progression-free survival. 47 However, only a small minority of IFN-treated patients achieve a stable CMR.
Cessation of IFN treatment in the minority of patients who achieve a deep molecular response may be associated with stable MMR for a period in excess of 9 years off treatment. 48, 49 Other IFN-treated patients have been reported in patients who remained in stable complete cytogenetic response after cessation of IFN. 50, 51 It seems likely that this stable level of MRD after cessation of IFN treatment may reflect ongoing immunological suppression of CML. IFN increases the expression of known leukaemia-associated antigens and is associated with the development of T cell responses against such antigens.
44,45
IFN may induce proliferation of CML stem cells, 42 thus contributing to stem cell exhaustion and providing a rationale for combination therapy with tyrosine kinase inhibitors, which are otherwise ineffective against quiescent CML stem cells. Extending this hypothesis, Burchert et al. 52 used combination therapy with IFN and imatinib and then stopped imatinib, using IFN as maintenance treatment. Cytotoxic T lymphocytes (CTLs) reactive against a leukaemia-associated antigen were observed more frequently after imatinib was stopped, and there was a suggestion that failure to develop this response was associated with an increase in the level of MRD.
Cessation of imatinib treatment
Mathematical modelling of relapsing CML using RQ-PCR data and model assumptions from stem cell biology predicts a rapid increase in BCR-ABL when treatment is withdrawn. 23, 24 In this model such increase is due to the unchecked proliferation of progeny derived from a pool of CML GMP precursors. The time taken for MRD to rise to a level that results in molecular relapse will depend on the proliferative capacity of the GMPs and on the size of the GMP pool (as well as on the lower detection limit of the assay). Given the high proliferative capacity of CML cells, it might be predicted that the size of the GMP pool at the time of imatinib cessation would be the primary determinant of the time to relapse. With an average relapse gradient of 0.02 log per day 23 the predicted time for unchecked proliferation of a single leukaemic cell to result in loss of CMR would be 10-12 months.
There is currently limited information on the outcome of CML patients after the cessation of imatinib treatment in CMR. A cohort of 12 patients was reported by the French CML Intergroup: those patients had a minimum duration of CMR of 2 years, and were monitored monthly with RQ-PCR after imatinib cessation. A total of six patients relapsed within the first 6 months, while the remaining 50% of patients were in stable CMR. 53 Only two patients in this pilot study had received imatinib treatment de novo and both of these patients relapsed. The remaining 10 patients had all received IFN therapy previously. A case report from the MD Anderson Cancer Center detailed for the first time stable CMR for more than 6 months after imatinib cessation in a single patient treated with imatinib de novo.
54
There are now at least two studies underway examining the outcome of chronic-phase CML patients following imatinib cessation in stable CMR. Interim results of the follow-up study from the French CML intergroup were reported in 2009: 55 with
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The last CML cell? DM Ross et al 69 patients enrolled and a median follow-up of 17 months, the relapse rate was 55%. Importantly, the relapse rate was similar in those patients who received imatinib de novo (54%) and those treated with imatinib after the previous IFN therapy (56%). A similar study, currently having enrolled 35 patients, is being conducted by the Australasian Leukaemia & Lymphoma Group. 19 At the most recent interim analysis (May 2010), the estimated molecular relapse rate was 60% with a median follow-up of 21 months. A total of 12 patients were in continuous CMR without any therapy for 12 months or more. Across both studies, only occasional relapses have occurred more than 6 months after stopping imatinib. The latest relapse to date was 24 months after imatinib cessation (in the Australasian study). It should be emphasized that in both of these studies relapse was defined as detectable BCR-ABL mRNA and, to the best of our knowledge, none of these patients has experienced a cytogenetic or haematological relapse of CML. Resumption of imatinib treatment after confirmation of molecular relapse typically restores CMR within 6 months.
Persistent MRD might not always result in relapse
There is an apparent dichotomy in imatinib-treated patients between early relapse and sustained remission, and we hypothesized that this could reflect differing levels of MRD, with those patients in remission having a lower level of MRD, or even having eradicated the CML clone. In a subset of 18 patients in the Australasian imatinib cessation study we used a sensitive, patient-specific DNA PCR method to show that a measurable level of MRD was present in most patients in CMR (Figure 1) . 19 This intronic sequence can then be amplified using a forward primer in BCR and a reverse primer in ABL1. The measured level of MRD in these patients was in the range of 0.5-1.5 log below the conventional RQ-PCR threshold for CMR. This is consistent with extrapolated RQ-PCR data, which would predict a level of MRD of around 1 log below the detection limit of RQ-PCR in most patients after 2 years in a stable CMR.
Several hypotheses might explain why a pool of viable leukaemic cells should not cause relapse. In transplantation models of leukaemia there may be a critical cell dose required to initiate leukaemia, but this probably reflects the rarity of true stem cells in a mixed population of leukaemic cells, rather than the need for a critical initiating mass of leukaemic progenitors. Second, the leukaemic cells that survive after imatinib treatment might be functionally defective or terminally differentiated (for example, memory B cells). An alternative explanation, for which there is currently the most evidence, is that MRD is suppressed below the limit of detection by an ongoing immunological response against the leukaemic clone.
Immunological control of CML
The best evidence for immunological suppression of the leukaemic clone in CML comes from patients with residual disease or relapse after allogeneic stem cell transplantation, supported by data from IFN-treated patients, as discussed above. There is a link between clinical response to IFN therapy and the emergence of CTLs specific for myeloid-associated antigens. 44 CML patients whose CD34 þ leukaemic cells expressed higher levels of the leukaemia-associated antigen, proteinase 3, had more indolent disease, 33 raising the possibility that a more immunogenic leukaemia is more effectively suppressed by the host immune system. There is conflicting evidence as to whether similar CTL responses also occur during imatinib treatment. 45, 56 In fact, rare CTLs against CML-associated antigens can be found even in the blood of normal individuals. 57 This is perhaps not surprising, given that many of the antigens associated with a CTL response in CML (and other myeloid malignancies) are widely expressed in normal cells. 58 Leukaemia-specific autologous CTLs can be elicited by peptide vaccination using the aminoacid sequence of the BCR-ABL junction, 59, 60 and there is preliminary evidence that an immunological response to vaccination might result in a clinically significant reduction in the level of MRD. 60, 61 Another interesting observation from allograft patients is the response to imatinib when used to treat relapse post-allograft: with or without donor lymphocyte infusion a stable CMR is typically achieved very quickly. 62, 63 This suggests that, after allografting, the suppression of MRD by imatinib might help to restore effective immunological control. Several studies have shown that CTL responses against leukaemia-associated antigens emerged or were augmented in response to a reduction in disease burden. 44, 56, 64 This finding has parallels in a mouse model of the immune response to chronic infection, 65 from which the authors concluded that a reduction in the antigenic burden (by chemotherapy) might be necessary to prevent functional impairment of the host immune response against a chronic pathogen. The importance of functional impairment of the anti-leukaemic CTL response was further demonstrated in a mouse model of CML in which upregulation of the programmed cell death-1 receptor was associated with immune exhaustion and disease progression. 66 Manipulation of the co-stimulatory molecules that contribute to immune exhaustion might in the future open up a novel class of therapeutics for CML.
Imatinib suppresses T cell function 67 and could potentially impair immune surveillance against CML. The more potent ABL kinase inhibitors, nilotinib and dasatinib, are both available in many countries for patients who have failed imatinib treatment, and clinical trials of de novo treatment with these drugs have shown promising responses. In the future it is possible that the use of more potent inhibitors of BCR-ABL will increase the proportion of patients who achieve a stable CMR. However, if immunological surveillance is important in determining the stability of CMR in imatinib-treated CML patients, then the more potent T cell immunosuppressive effects of dasatinib [68] [69] [70] and nilotinib 71 might alter the risk of relapse when therapy is withdrawn. Intriguingly, despite such theoretical concerns, the emergence of increased numbers of large granular lymphocytes in the peripheral blood (CTL or natural killer cell type) has been observed during dasatinib treatment and appears to be associated with improved CML responses. 72 
Disease resistance and progression
The primary aim of all treatments for chronic-phase CML is to prevent progression to accelerated phase or blast crisis. After transformation, the response to therapy is poor and blast crisis carries a life expectancy of less than 12 months. 73, 74 The mechanisms of transformation are complex, but in most cases the acquisition of new genetic abnormalities is essential for the activation of pathways that confer resistance to treatment. 75 DNA damage is a stochastic process, so a smaller number of 'at-risk' cells must translate into a lower probability that a resistant mutation will arise. This theoretical consideration is supported by the strong relationship between the level of MRD achieved during treatment and the subsequent risk of disease progression.
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The last CML cell? DM Ross et al BCR-ABL is itself mutagenic: the genome of a CML cell has an increased rate of mutation due to a combination of increased damage by reactive oxygen species 76 and defective DNA repair. [77] [78] [79] These abnormalities are at least partly dependent on BCR-ABL kinase activity, so the effective inhibition of BCR-ABL by imatinib would be expected to reduce the risk of acquiring a new mutation. Imatinib treatment of CML cells in vitro results in the accumulation of quiescent CML precursors that are resistant to imatinib. 28, 29 These cells are not in active cell cycle, and it is unclear whether or not they are protected from DNA damage so long as they remain quiescent. BCR-ABL mRNA is expressed in CML stem cells 34, 35 and BCR-ABL kinase activity (measured as protein substrate phosphorylation) may persist in CD34 þ CD38À CML stem cells exposed to imatinib ex vivo. 35 If mutagenesis is not suppressed in CML precursors that survive treatment, then a small risk of disease progression will persist as long as there are any viable CML cells.
Do we have to kill the last CML cell?
At present, this must remain a rhetorical question, as we do not (and probably never will) have the ability to measure the 'last CML cell'. This question can really be answered only by the careful observation of patients who stop therapy in CMR; however, if relapse can occur 20 years after an allograft, then how long must we wait for an answer?
Any persistence of BCR-ABL in viable leukaemic stem cells or early progenitors must result in a lasting risk of relapse and disease progression, and therefore complete eradication should be our goal. If the risk of disease progression is as small in imatinib-treated patients as it is in patients in long-term remission after allografting, then a pragmatic response may be that eradication is not necessary. If it is true that stem cell exhaustion is common in CML, as predicted by Lenaerts et al., 36 then perhaps we need only to suppress the disease for long enough and it will burn itself out.
Two ongoing studies of imatinib cessation suggest that around 40% of patients with a durable CMR on imatinib treatment may remain in CMR when treatment is withdrawn, and it is possible that CML has been eradicated in some of these patients. A longer follow-up of patients in stable CMR without imatinib treatment is needed to determine whether these patients can be considered to have been cured. At least it is clear that early relapse is not inevitable when imatinib treatment is withdrawn from carefully selected patients. Further progress on (1) the measurement of low levels of MRD; (2) better understanding of the pathways in leukaemic cells that determine response to therapy and persistence of MRD; and (3) definition of the role of immunological reactivity against CML is needed. These studies might enable us prospectively to identify imatinib-treated patients who have a low risk of relapse when treatment is stopped.
